세계의 불면증 치료제 시장 : 유형별, 유통 채널별 예측(2025-2030년)

The Insomnia Drugs Market was valued at USD 2.92 billion in 2023, expected to reach USD 3.07 billion in 2024, and is projected to grow at a CAGR of 5.67%, to USD 4.30 billion by 2030.

The insomnia drugs market encompasses pharmaceutical products designed to improve sleep quality and duration in individuals experiencing insomnia. Insomnia, characterized by difficulty in falling or staying asleep, necessitates effective medications like benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. The growing prevalence of insomnia, driven by stress, lifestyle changes, and an aging population, underscores the market's necessity. It finds application across various end-users, including hospitals, clinics, and homecare settings, aiming to improve patient quality of life by restoring regular sleep patterns. Key growth factors include the increasing awareness of mental health and the need for advanced sleep disorder treatments. Additionally, rising healthcare expenditure and technological advancements in drug formulation present potential opportunities. Expanding the accessibility of treatments through telemedicine platforms and collaborations with healthcare providers can enhance market reach. However, challenges persist in the form of side effects associated with long-term usage, stringent regulatory approvals, and the emergence of side-effect-free alternative therapies like cognitive behavioral therapy. Addressing these limitations involves research focused on developing drugs with reduced adverse effects and personalized medicine approaches for individualized treatment regimens. Innovations in rapid drug delivery systems and drugs targeting core sleep-regulating pathways could advance market growth. Investment in R&D for non-addictive, natural, and sustainable sleep aid products could differentiate companies within this competitive market. Moreover, utilizing digital health tools, such as wearable technology and sleep monitoring apps, offers opportunities to enhance patient engagement and outcome tracking, providing valuable real-world data insights. Despite current challenges, the market holds significant promise for growth, particularly in the development of synergistic therapies, integrating pharmacological treatments with lifestyle interventions tailored to patient needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insomnia Drugs Market

The Insomnia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of insomnia across the world
  • Rising awareness about various treatment options available for insomnia
• Market Restraints
  • Side effects associated with insomnia drugs
• Market Opportunities
  • Continuous research and development to develop novel insomnia drugs
  • Increase in number of insomnia centers and sleep diagnostic centers
• Market Challenges
  • Misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Insomnia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insomnia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insomnia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insomnia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insomnia Drugs Market

A detailed market share analysis in the Insomnia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insomnia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insomnia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Insomnia Drugs Market

A strategic analysis of the Insomnia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Insomnia Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Aurobindo Pharma Limited, Biogen SA, Cadila Healthcare Ltd., Dr.Reddy's Laboratories Limited, Eisai Co., Ltd., Eli Lilly and Company, Flynn Pharma Limited, Glenmark Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd., LA Herbal (India), Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Minerva Neurosciences, Inc., Neuracle Lifesciences Private Limited, Neurim Pharmaceuticals LTD., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Sanofi Group, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Vanda Pharmaceuticals Inc., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Insomnia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Anti-Parkinsonian Drugs, Anticonvulsants, Antidepressants, Antinarcoleptics, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Ramelteon.
• Based on Distribution Channels, market is studied across Online Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of insomnia across the world
    • 5.1.1.2. Rising awareness about various treatment options available for insomnia
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with insomnia drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous research and development to develop novel insomnia drugs
    • 5.1.3.2. Increase in number of insomnia centers and sleep diagnostic centers
  • 5.1.4. Challenges
    • 5.1.4.1. Misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Insomnia Drugs Market, by Type

• 6.1. Introduction
• 6.2. Anti-Parkinsonian Drugs
• 6.3. Anticonvulsants
• 6.4. Antidepressants
• 6.5. Antinarcoleptics
• 6.6. Benzodiazepines
• 6.7. Nonbenzodiazepines
• 6.8. Orexin Antagonist
• 6.9. Ramelteon

7. Insomnia Drugs Market, by Distribution Channels

• 7.1. Introduction
• 7.2. Online Pharmacies
• 7.3. Retail Pharmacies

8. Americas Insomnia Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Insomnia Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Insomnia Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals Limited
• 2. Astellas Pharma Inc.
• 3. Aurobindo Pharma Limited
• 4. Biogen SA
• 5. Cadila Healthcare Ltd.
• 6. Dr.Reddy's Laboratories Limited
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. Flynn Pharma Limited
• 10. Glenmark Pharmaceuticals Ltd.
• 11. Idorsia Pharmaceuticals Ltd.
• 12. LA Herbal (India)
• 13. Mallinckrodt Pharmaceuticals
• 14. Merck & Co., Inc.
• 15. Minerva Neurosciences, Inc.
• 16. Neuracle Lifesciences Private Limited
• 17. Neurim Pharmaceuticals LTD.
• 18. Orexo AB
• 19. Pfizer Inc.
• 20. Purdue Pharma L.P.
• 21. Sanofi Group
• 22. Sun Pharmaceutical Industries Limited
• 23. Takeda Pharmaceutical Company Limited
• 24. Vanda Pharmaceuticals Inc.
• 25. Wockhardt Limited